cyrilzakka/clinical-trials huggingface dataset:
AI Models to Predict Thyroid Cartilage Invasion in Laryngeal Carcinoma

This retrospective study was to develop and verify CT-based AI model to preoperatively predict the thyroid cartilage invasion of laryngeal cancer patients, so as to provide more accurate diagnosis and treatment basis for clinicians. In addition, the researchers investigated the prediction of survival outcomes of patients by the above optimal models.

Laryngeal squamous cell carcinoma (LSCC), as one of the most common head and neck tumors, is the eighth leading cause of cancer-associated death worldwide. The treatment decisions has a profound impact on both tumor control and functional prognosis of LSCC patients. And these decisions are primarily based on tumor staging, with the invasion of the thyroid cartilage serving as a crucial determinant. Consequently, the presence of thyroid cartilage invasion indicates an advanced stage (T3 or T4) diagnosis for the LSCC patients. For patients without thyroid cartilage invasion, partial laryngectomy may be considered to preserve laryngeal function. However, for patients with advanced laryngeal carcinoma and thyroid cartilage invasion extending beyond the larynx, total laryngectomy is often necessary to completely remove the tumor and extend survival time. Therefore, accurate assessment of thyroid cartilage invasion is vital for treatment decision-making and prognosis evaluation for LSCC patients.

Eligibility Criteria:
Inclusion Criteria:

1. Availability of complete clinical data
2. Surgery-proven or biopsy-proven diagnosis of laryngeal squamous cell carcinoma
3. CT examination performed within 2 weeks before surgery

Exclusion Criteria:

1. Patients who received preoperative chemotherapy or radiation therapy
2. CT images with significant artifacts
3. Patients with tumor recurrence
Comparison of the Strength of Maximum Glute and Medium Glutenum Muscles Of Latin and Active Lombar Guidelines

Contextualization: Trigger points are muscle nodules found in muscles. We can observe five different types of trigger point, in clinical practice two of them stand out, the active trigger point; Which is painful; And latent; Asymptomatic; Both of which are sensitive to palpation. Once the individual present these muscle nodules can develop pain and motor dysfunction. Studies indicate that the prevalence of trigger points is 95% of individuals with chronic musculoskeletal pain, but this prevalence is not yet clear in individuals with low back pain.

Objective: To compare the pain and function levels of patients with acute and chronic low back pain who, when asymptomatic, had trigger points compared to the pain and function levels of patients with acute and chronic low back pain who, when asymptomatic, had no trigger points.

Study design: Cohort study, two arms, blind evaluator, prospectively enrolled at baseline.

Location: This research will be conducted in the physiotherapy department at the Rehabilitation Center of the Brotherhood of Santa Casa de Misericórdia de São Paulo (ISCMSP).

Patients: 400 asymptomatic individuals Follow-up: Asymptomatic individuals will be assessed at baseline and over 3 years. You will be asked to contact the research department within 6 weeks of low back pain (acute) and after 12 weeks of low back pain (chronic). Participants will be allocated to two groups, trigger point group (n = 200) and group without trigger point (n = 200).

Outcomes: The pain intensity, function level and trigger point pain intensity outcomes will be evaluated at the baseline, within 6 weeks for the patient to present pain in the lumbar (acute) and after 12 weeks the pain persists (chronic)


Eligibility Criteria:
Inclusion Criteria:

* Men and women;
* Age between 18 - 40 years;
* Asymptomatic;
* There is no treatment for lumbar spine, hip or knee.

Exclusion Criteria:

* Anterior lumbar spine surgeries;
* Severe spinal diseases (fracture, tumor, ankylosing spondylitis);
* Root conditions (herniated disc, spondylolisthesis);
* Congenital malformation;
* Pregnant women.
Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects

This study's primary objective is to determine the ability of Kombucha to impact blood sugar levels in patients with diabetes mellitus type II. The secondary objective is to determine the ability of Kombucha to impact blood pressure, and quality of life measures as measured by uniform questionnaire that includes: gut health, colds, infections, headaches, sleep, anxiety (GAD2), depression (PHQ2), skin health.


Eligibility Criteria:
Inclusion Criteria:

1. S/he is above the age of 18
2. S/he has the ability to read, speak and write English
3. S/he has telephone access
4. S/he is diabetic and willing to check blood sugar levels every day
5. Hb A1c \>7%
6. Possesses a glucometer

Exclusion Criteria:

1. Allergy to kombucha ingredients
2. Drinks kombucha regularly (\>3time per week)
Acetylated Natural Nucleotides in Treating Hand-foot Syndrome

The clinical trial is planned to investigate the efficacy and safety of acetylated natural nucleotides in treating anti-cancer medications induced hand-foot syndrome (HFS).


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older.
* Pathologically conﬁrmed cancer receiving capecitabine-based anti-cancer therapy (capecitabine with or without other anti-cancer drugs).
* With HFS determined by "CTCAE v5.0 - PPE" as grade 2 or above.
* Able to use topical medications and complete questionnaires reliably with or without assistance.
* ECOG performance score \< 2.

Exclusion Criteria:

* Has HFS due to other medications and does not recover within 4 weeks prior to baseline.
* Other skin disorders that will affect efficacy evaluation on the hands and feet, including but not limited to: tinea of feet and hands, hand/foot eczema, palmoplantar pustulosis, palmoplantar keratosis, acrodermatitis continua etc.
* Uncontrolled intercurrent illness as determined by the investigator including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, recent myocardial infarction, uncontrolled hypotension or hypertension, cardiac arrhythmia, or psychiatric illness and social situations that would limit compliance with study requirements.
* Significantly abnormal lab test:

  * Inadequate hematologic function as indicated by:

    * Absolute neutrophil counts (ANC) \< 1,500 /mm\^3
    * Hemoglobin (Hgb) \< 8.5 g/dL
    * Platelet count \< 75,000 /mm\^3
    * PT or PTT \> 1.5 x ULN (if patients on anticoagulants: PT INR \> 3.5 x ULN)
  * Inadequate renal and liver function as indicated by:

    * Albumin \< 2.8 g/dL
    * Total bilirubin \> 1.5 x ULN (or \> 2.5 x ULN for patients with Gilbert's syndrome)
    * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase \> 2 x ULN
    * Creatinine \> 2 x ULN
* Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples

To look for patterns of polymorphisms in DNA repair in both germline and tumor cells samples.


Eligibility Criteria:
Inclusion Criteria:Pediatric cancer patients diagnosed with brain tumors
Study of Systemic Amyloidosis Presentation and Prognosis

OBJECTIVES: I. Analyze prospectively the course of amyloid deposition in patients with primary, secondary, myeloma-associated, and hereditary amyloidosis.

II. Determine abnormalities of humoral and delayed-type hypersensitivity in these patients.

III. Identify prognostic factors in hereditary amyloidosis and develop tests for genetic defects associated with systemic amyloidosis.

IV. Diagnose familial amyloidotic polyneuropathy (FAP) prior to symptom onset. V. Validate the correlation of low serum prealbumin and retinol binding protein levels with amyloidosis in patients with FAP.

PROTOCOL OUTLINE: Patients receive a comprehensive evaluation with an emphasis on identifying prognostic and diagnostic factors. Assessments include gastrointestinal, renal, hematologic, dermatologic, cardiac, and serologic studies. Immunologic studies include antinuclear antibody, latex fixation, and serum and urine electrophoresis.

Genetic trees are constructed using detailed family history data; blood and urine samples are routinely collected from relatives. Family members of patients with familial amyloidotic polyneuropathy type II (Indiana type) undergo a flexor retinaculum biopsy of the wrist.

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Systemic amyloidosis, i.e.: Primary, myeloma associated Secondary, e.g., associated with the following conditions: Rheumatoid arthritis Inflammatory bowel disease
Circulating Biomarkers and Ventricular Tachyarrhythmia

The purpose of this study is to determine whether levels of inflammatory markers in circulating blood can correlate with risk for dangerous heart rhythms. Patients with systolic heart failure, which has been shown to increase risk for dangerous heart rhythms, will be enrolled. All subjects will have an implantable cardioverter-defibrillator (ICD) in place, which allows regular evaluation of heart rhythm.

If you agree to be in this study, you will be asked to the following things:

* you will come into the EP device clinic every three months for one year to have your device interrogated and will complete an EKG
* you will have labs drawn to measure levels of certain markers of inflammation in the body. This information will be used to identify new ways to test for risk of abnormal heart rhythms and other heart disease
* you will review your medications with the study coordinator and along with any recent illnesses or hospitalizations

Eligibility Criteria:
Inclusion Criteria:

* left ventricular ejection fraction \[LVEF\] \<=35%
* ICD implant

Exclusion Criteria:

* Recent myocardial infarction (12 weeks)
* Recent revascularization (12 weeks)
* Recent hospitalization for any cause (6 weeks)
* History of rheumatologic disease
Effect of Mouthwash in Reducing the Symptoms Associated With Flu and Cold Viruses

The aim of this study will be to evaluate the efficacy of regular cleaning of the oropharynx (via gargling) on the incidence of symptoms associated with flu and colds. The working hypothesis is that there will be a significant reduction in symptoms associated with flu and colds after using the mouthwash product, compared to the experimental control regime. A total of 150 individuals will be randomized to one of the two experimental regimens and followed for a period of 90 days. The experimental regimen consists of toothbrushing followed by gargling with a cetylpyridinium chloride (CPC) (0.075%) and zinc containing alcohol free rinse and the control regimen consists of toothbrushing alone. Participants will be instructed to brush their teeth twice a day for two minutes. Those allocated to the test regime will gargle with 20 ml of the mouthwash after each brushing. At the initial visit, participants will receive the products and instructions for use, as well as a daily log questionnaire. Participants will be asked to send their daily records once a week, using a messaging application. The proportion of days without any of the evaluated symptoms will be used as the main outcome. In addition, soft and hard tissue exams will be performed at the initial consultation, after 30 and 90 days of follow-up by a blinded researcher. Potential adverse events will be collected throughout the study. The groups will be compared using the chi-square test and one-way analysis of variance (ANOVA) will be used to compare the treatment group symptom rates between groups. The significance level will be set at 95%.


Eligibility Criteria:
Inclusion Criteria:

* Good systemic general health as determined by study investigators; Availability of 90 days to participate in the study;

Exclusion Criteria:

1. Those participating in any other clinical study; 2. Pregnant or breastfeeding; 3. Presence a history of allergies to oral hygiene products, personal hygiene products, or their ingredients; 4. Have mouth irritation or use oral anesthetic sprays; 5. Have diabetes; 6. Be undergoing extensive dental treatment or oral surgery during the study; 7. Present immunocompromised (HIV, AIDS, immunosuppressive drug therapy); 8. Use complete dentures; 9. Do not have carpal tunnel syndrome or arthritis in the hands. 10. Participant who substantially fails to follow the required protocols; 11. Participant who fails to attend scheduled appointments; 12. Participant who is treated, during the study period, with medications that may interfere with the parameters being analyzed in the study; 13. Participant who is treated by a medical or dental service, and this may interfere with the parameters being analyzed in the study; 14. Participant who develops serious adverse reactions. 15. The participant who chooses to terminate their participation in the study; 16. Participant reports being pregnant during the study.
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease

The gut may be a portal of entry for agents that cause or contribute to the causes of Parkinson's disease (PD). The investigators are studying changes in the normal population of gut flora and in intestinal permeability and their associations with early PD.

Clinical and pathological data suggest Parkinson's disease (PD) may result from an inflammatory process beginning in the intestinal wall that initiates alpha-synuclein aggregation, which then spreads from neuron to neuron, reaching the central nervous system. Bacteria living within the intestinal tract produce lipopolysaccharide endotoxin, a toxin known to induce parkinsonism in animal models. We hypothesize that exposure to LPS, either from excessive production or excessive absorption may be the cause of this inflammation. This study aims to: (1) describe differences in the population of gut bacteria in PD compared to control subjects; (2) assess leakiness of the gut wall by differential absorption of non-absorbable sugars; (3) measure plasma levels of endotoxin and inflammation; and (4) study characteristic PD pathology and evidence of inflammation in biopsy samples of the colon obtained by sigmoidoscopy.

Eligibility Criteria:
Inclusion Criteria--Parkinson's disease:

* Clinically diagnosed Parkinson's disease
* Hoehn \& Yahr stage 1-2.5
* No symptomatic treatment of Parkinson's disease symptoms

Inclusion Criteria--Multiple System Atrophy

* Clinically diagnosed Multiple System Atrophy.

Inclusion Criteria--Control subjects:

* No diagnosis of Parkinson's disease and no signs of Parkinson's disease on screening neurological examination

Exclusion Criteria:

* Secondary or atypical parkinsonism other than Multiple System Atrophy
* Occupation or medical treatment known to influence intestinal flora
* Organic gastrointestinal disease other than hiatal hernia or hemorrhoids; history of gastrointestinal surgery other than remote appendectomy or cholecystectomy.
* Acute or chronic medical illness that would confound study results.
* Coagulopathy or use of anticoagulant medications (including aspirin).
* Chronic use of diuretics
Accelerated Corneal Cross-linking With Different Riboflavin Solutions

Following the Bunsen-Roscoe law, accelerated cross-linking protocols with higher irradiation intensities and shorter irradiation times have been introduced. In addition, new riboflavin solutions with HPMC (hydroxylpropyl methylcellulose) instead of dextran found its way into CXL-treatment. The aim of this trial is to evaluate clinical outcomes in an accelerated corneal collagen cross-linking protocol with different riboflavin solutions.


Eligibility Criteria:
Inclusion Criteria:

* Progressive Keratoconus
* Indication for treatment
* Preoperative Pachymetry \> 400

Exclusion Criteria:

* Pregnancy
* Re-CXL
* Keratitis
* Other visual acuity limiting eye diseases than corneal ectatic diseases
Pioglitazone for Lung Cancer Chemoprevention

This is a chemoprevention trial evaluating the diabetic agent pioglitazone. Non-diabetic subjects at risk for lung cancer (based on smoking history, lung function testing, and atypical cells in a sputum sample) receive either placebo or pioglitazone and have chest computerized tomography (CAT) scans and examinations of their airways with a bronchoscope at the start of the trial and after 6 months on treatment. Compensation will be provided to the subject after completing the trial.

This trial evaluates the oral peroxisome proliferator-activated receptor gamma (PPARgamma) agonist pioglitazone in a double-blind placebo controlled trial. The high risk current and former smokers qualify based on tobacco exposure, airflow limitation on lung function testing, and sputum cytologic atypia. Subjects have a quantitative high resolution thoracic CT scan and a fluorescent bronchoscopy at study entry and after 6 months on drug or placebo. Biologic samples are collected at both time points. The primary outcome is endobronchial histology and determining if pioglitazone can retard progression. Secondary endpoints related to the PPAR gamma signaling pathway will also be analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Current or former smoker (at least 10 pack years);
* One or more of the following:
* Mild or worse sputum atypia
* Airflow Limitation (FEV1/FVC\<70% predicted)
* Biopsy proven airway dysplasia

Exclusion Criteria:

* myocardial infarction (MI) with ejection fraction \< 50%;
* severe/unstable angina;
* history of coronary or peripheral arterial bypass grafting;
* New York Heart Association (NYHA) class III or IV congestive heart failure;
* hypoxemia (less than POX 90 with supplemental oxygen); Diabetes type I or II; severe COPD (GOLD stage III or IV); clinically significant edema requiring diuretic therapy;
* life expectancy \< 6 months; history of bladder cancer
* pregnant or breast feeding; inability to give informed consent
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement

Polyphenolic compounds are very strong Inhibitors of non-heme iron absorption, as they form insoluble complexes with ferrous iron. Patients with hereditary hemochromatosis (HH) have an increased intestinal non-heme iron absorption due to a genetic mutation in the regulatory pathway, leading to excess iron in the body. This study investigates the inhibitory effect of a natural polyphenol Supplement in participants with HH.


Eligibility Criteria:
Inclusion Criteria:

* Homozygous for C282Y mutation in HFE (hemochromatosis) gene
* Written informed consent
* Age 18-65 y
* Not pregnant or lactating
* Body weight \< 75 kg
* Body mass index (BMI) between 18.5 and 25 kg/m2
* No acute illness/infection (self-reported)
* No metabolic or gastrointestinal disorders, eating disorders or food allergy to the ingredients of the test meal (self-reported)
* No scheduled phlebotomy throughout the study period
* The last phlebotomy will be at least 4 weeks prior first test meal administration
* No use of medications affecting iron absorption or metabolism during the study
* No intake of mineral/vitamin supplements 2 weeks before the first study day and during the study
* Participation in any other clinical study within the last 30 days
* Expected to comply with study protocol
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

The purpose of this study is to test whether Lomecel-B™ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue inside of your bones. Lomecel-B uses MSCs from bone marrow of unrelated young healthy donors. These are called "allogeneic", and do not require donor matching to the patient.


Eligibility Criteria:
Inclusion:

All participants must have HLHS (includes all types) requiring Stage II palliation (Glenn or Hemi-Fontan operation).

Exclusion:

1. Requirement for ongoing mechanical circulatory support immediately prior to Stage II palliation within 5 days
2. Need for concomitant surgery for aortic coarctation or tricuspid valve repair or Endocardial fibroelastosis (EFE) resection or left ventricle recruitment procedures
3. Undergoing the Stage I (Norwood) procedure that does not have HLHS
4. Serum positivity for: human immunodeficiency virus (HIV); hepatitis B virus surface antigen (HBV BsAg); and/or viremic hepatitis C virus (HCV). This criterion can be ascertained by one of three ways:

   1. Documented history of mother's testing conducted during pregnancy
   2. Documented history of participants testing.
   3. If above documentation is not available blood will be obtained from participant at Screening/Baseline.
5. Parent/guardian that is unwilling or unable to comply with necessary follow-up
6. Unsuitability for the study based on the Investigator's clinical opinion
7. Known hypersensitivity to dimethyl sulfoxide (DMSO)
8. Presence of a pacemaker, or anticipated placement of a pacemaker, at the time of the Stage II palliation
Robotic Total Hip Arthroplasty Anesthesia Management

Robotic arthroplasty is increasing in acceptance on a global scale as a result of advancements in orthopedic surgery technology. The investigators aimed to share their anesthesia management experience as well as compare robotic unilateral total hip arthroplasty with conventional surgical technique in this retrospective study.

This study was conducted after obtaining ethics committee approval.

The inclusion criteria were as follows: American Society of Anesthesiologists (ASA) physical status I-III patients between 40-85 years, elective unilateral THAs which were performed by a single senior orthopedic surgeon and orthopedic team between January 2021 and January 2023 under CSEA. Exclusion criteria were urgent surgery, bilateral surgery, previous surgery, missing data, and lost to follow-up in the perioperative period.

The routine anesthetic protocol for the TKA was as follows: A single dose of 0.5% hyperbaric bupivacaine between 15-10 mg was administered intratechally. Following this the epidural catheter was inserted 4 cm into the epidural space through the epidural needle and secured. The level of the sensory block was assessed using pin-prick and cold sensation tests, and motor block using the Bromage scale. The patients were followed in the postanesthesia care unit (PACU) after the surgery. Patients with a modified Aldrete scoring system ≥9 were considered to be eligible for the transfer from PACU to the service.

Pain was evaluated using a Visual Analogue Scale (VAS) with regular intervals. Data were collected from hospital's electronic database records, patient files, and anesthesia charts.

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I-III
* Between 40-85 years
* Elective unilateral THAs which were performed by a single senior orthopedic surgeon
* Between January 2021 and January 2023 under CSEA.

Exclusion Criteria:

* Urgent surgery
* Bilateral surgery
* Previous surgery
* Missing data and lost to follow-up in the perioperative period